COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00376233
Recruitment Status : Completed
First Posted : September 14, 2006
Last Update Posted : October 12, 2006
Information provided by:
University of Jena

Brief Summary:

Increasing evidence suggests modulating effects of cannabinoids on time of onset, severity, and outcome of schizophrenia. Efforts to discover the underlying pathomechanism have led to the assumption of gene x environment interactions including premorbid genetical vulnerability and worsening effects of continuing cannabis use. For a main characteristic of psychoactive delta-9-tetrahydrocannabinol is its affinity to biological membranes, which are known to be disturbed in schizophrenia patients and genetic high-risk populations.

Here we assess an hypothesised association between premorbid lipid disturbance and metabolic effects of external cannabinoids in schizophrenia.

Intensity of niacin (methylnicotinate) skin flushing, indicating disturbed prostaglandin-mediated processes, is used as peripheral marker of lipid-arachidonic acid pathways and investigated in cannabis consuming and non-consuming schizophrenia patients and in healthy controls. Methylnicotinate is applied in three concentrations onto the forearm skin. Flush response is assessed in three minute intervals over 15 min using optical reflection spectroscopy.

Condition or disease
Schizophrenia Cannabis Abuse

Show Show detailed description

Layout table for study information
Study Type : Observational
Enrollment : 100 participants
Observational Model: Defined Population
Time Perspective: Other
Official Title: First Detailed Study on Effects of Long Term Regular Cannabis Use on Arachidonic Acid-Prostaglandine Pathways in Schizophrenia
Study Start Date : February 2004
Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:


  • acutely ill
  • consecutively admitted
  • diagnosis of schizophrenia according to DSM-IV criteria for paranoide schizophrenia.
  • not treated or treated with atypical neuroleptic drugs
  • cannabis use on a regular basis (≥ 0,5 g/d, at least 3 month) prior to admission or
  • never use of cannabis apart from unique trials
  • no use of any other drug or alcohol on a regular basis.


  • healthy volunteers recruited by newspaper advertisement
  • cannabis user (duration and dose of cannabis use as in patients)or
  • no cannabis experience at all

All cannabis consuming participants:

  • positive for cannabinoids in urine test at the time of niacin testing

Exclusion Criteria:


  • current psychiatric diagnosis or psychiatric personal or family history.

All individuals:

  • any current or history of skin disorders (eczema, atopical dermatitis, psoriasis)
  • recent treatment with steroids or non-steroidal antiinflammatory drugs (e.g. acetylsalicylic acid)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00376233

Layout table for location information
University of Jena, Department of Psychiatry
Jena, Thueringen, Germany, D-07743
Sponsors and Collaborators
University of Jena
Layout table for investigator information
Study Director: Heinrich Sauer, PhD University of Jena
Additional Information:
Layout table for additonal information Identifier: NCT00376233    
Other Study ID Numbers: SMCANNIACIN
First Posted: September 14, 2006    Key Record Dates
Last Update Posted: October 12, 2006
Last Verified: September 2006
Keywords provided by University of Jena:
Arachidonic Acid,
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Abuse
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Substance-Related Disorders
Chemically-Induced Disorders